Do analysts recommend RXRX or INDP?

Recursion Pharmaceuticals currently has a consensus price target of $8.10, indicating a potential upside of 113.16%. Given Recursion Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Recursion Pharmaceuticals is more favorable than Indaptus Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Recursion Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20 Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate SEPN or INDP?

Septerna presently has a consensus target price of $45.89, indicating a potential upside of 34.97%. Given Septerna's stronger consensus rating and higher possible upside, analysts clearly believe Septerna is more favorable than Indaptus Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Septerna 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.82 Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend INDP or BCAX?

Bicara Therapeutics has a consensus target price of $30.27, suggesting a potential upside of 4.39%. Given Bicara Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Bicara Therapeutics is more favorable than Indaptus Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Bicara Therapeutics 1 Sell rating(s) 3 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.73

Which has stronger valuation and earnings, INDP or BCAX?

Bicara Therapeutics is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Indaptus Therapeutics N/A N/A -$20.85M -$15.40 N/A Bicara Therapeutics N/A N/A -$137.95M -$2.78 N/A

Is INDP or BCAX more profitable?

Bicara Therapeutics' return on equity of -35.89% beat Indaptus Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Indaptus Therapeutics N/A -1,030.07% -299.69% Bicara Therapeutics N/A -35.89% -33.78%

Do analysts rate INDP or TRLV?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Trulieve Cannabis 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has better earnings and valuation, INDP or TRLV?

Trulieve Cannabis has higher revenue and earnings than Indaptus Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Indaptus Therapeutics N/A N/A -$20.85M -$15.40 N/A Trulieve Cannabis $1.17B 1.60 N/A N/A N/A

Is INDP or TRLV more profitable?

Trulieve Cannabis' return on equity of 0.00% beat Indaptus Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Indaptus Therapeutics N/A -1,030.07% -299.69% Trulieve Cannabis N/A N/A N/A

Do analysts rate INDP or GHRS?

GH Research has a consensus price target of $40.38, suggesting a potential upside of 49.48%. Given GH Research's stronger consensus rating and higher probable upside, analysts clearly believe GH Research is more favorable than Indaptus Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 GH Research 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.73

Which has stronger earnings and valuation, INDP or GHRS?

GH Research is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Indaptus Therapeutics N/A N/A -$20.85M -$15.40 N/A GH Research N/A N/A -$48.26M -$0.92 N/A

Is INDP or GHRS more profitable?

GH Research's return on equity of -19.36% beat Indaptus Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Indaptus Therapeutics N/A -1,030.07% -299.69% GH Research N/A -19.36% -18.73%

Indaptus Therapeutics (INDP) Competitors

$3.03 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$3.03 0.00 (0.00%)

As of 07/2/2026 05:55 PM Eastern

Compare

INDP vs. RXRX, SEPN, BCAX, TRLV, and GHRS

Should you buy Indaptus Therapeutics stock or one of its competitors? MarketBeat compares Indaptus Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Indaptus Therapeutics include Recursion Pharmaceuticals (RXRX), Septerna (SEPN), Bicara Therapeutics (BCAX), Trulieve Cannabis (TRLV), and GH Research (GHRS). These companies are all part of the "pharmaceutical products" industry.

How does Indaptus Therapeutics compare to Recursion Pharmaceuticals?

Recursion Pharmaceuticals (NASDAQ:RXRX) and Indaptus Therapeutics (NASDAQ:INDP) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Recursion Pharmaceuticals has a beta of 1, suggesting that its share price has a similar volatility profile to the broader market.Comparatively, Indaptus Therapeutics has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market.

89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are owned by institutional investors. 6.7% of Recursion Pharmaceuticals shares are owned by insiders. Comparatively, 23.6% of Indaptus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Indaptus Therapeutics has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -842.95%. Recursion Pharmaceuticals' return on equity of -54.33% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-842.95%	-54.33%	-40.60%
Indaptus Therapeutics	N/A	-1,030.07%	-299.69%

Recursion Pharmaceuticals currently has a consensus price target of $8.10, indicating a potential upside of 113.16%. Given Recursion Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Recursion Pharmaceuticals is more favorable than Indaptus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Indaptus Therapeutics has lower revenue, but higher earnings than Recursion Pharmaceuticals. Recursion Pharmaceuticals is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$74.68M	26.96	-$644.76M	-$1.20	N/A
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$15.40	N/A

In the previous week, Recursion Pharmaceuticals had 8 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 8 mentions for Recursion Pharmaceuticals and 0 mentions for Indaptus Therapeutics. Recursion Pharmaceuticals' average media sentiment score of 0.81 beat Indaptus Therapeutics' score of 0.00 indicating that Recursion Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Recursion Pharmaceuticals	Positive
Indaptus Therapeutics	Neutral

Summary

Recursion Pharmaceuticals beats Indaptus Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Indaptus Therapeutics compare to Septerna?

Septerna (NASDAQ:SEPN) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

Septerna presently has a consensus target price of $45.89, indicating a potential upside of 34.97%. Given Septerna's stronger consensus rating and higher possible upside, analysts clearly believe Septerna is more favorable than Indaptus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Septerna had 12 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 12 mentions for Septerna and 0 mentions for Indaptus Therapeutics. Septerna's average media sentiment score of 0.09 beat Indaptus Therapeutics' score of 0.00 indicating that Septerna is being referred to more favorably in the media.

Company	Overall Sentiment
Septerna	Neutral
Indaptus Therapeutics	Neutral

7.1% of Indaptus Therapeutics shares are owned by institutional investors. 5.8% of Septerna shares are owned by company insiders. Comparatively, 23.6% of Indaptus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Septerna has a beta of 2.29, meaning that its stock price is 129% more volatile than the broader market. Comparatively, Indaptus Therapeutics has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market.

Indaptus Therapeutics has lower revenue, but higher earnings than Septerna. Septerna is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Septerna	$45.95M	33.36	-$48.88M	-$0.81	N/A
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$15.40	N/A

Indaptus Therapeutics has a net margin of 0.00% compared to Septerna's net margin of -49.88%. Septerna's return on equity of -12.72% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Septerna	-49.88%	-12.72%	-8.87%
Indaptus Therapeutics	N/A	-1,030.07%	-299.69%

Summary

Septerna beats Indaptus Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Indaptus Therapeutics compare to Bicara Therapeutics?

Indaptus Therapeutics (NASDAQ:INDP) and Bicara Therapeutics (NASDAQ:BCAX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, risk and profitability.

7.1% of Indaptus Therapeutics shares are held by institutional investors. 23.6% of Indaptus Therapeutics shares are held by company insiders. Comparatively, 13.8% of Bicara Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Bicara Therapeutics has a consensus target price of $30.27, suggesting a potential upside of 4.39%. Given Bicara Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Bicara Therapeutics is more favorable than Indaptus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73

Bicara Therapeutics is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$15.40	N/A
Bicara Therapeutics	N/A	N/A	-$137.95M	-$2.78	N/A

Bicara Therapeutics' return on equity of -35.89% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indaptus Therapeutics	N/A	-1,030.07%	-299.69%
Bicara Therapeutics	N/A	-35.89%	-33.78%

Indaptus Therapeutics has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market. Comparatively, Bicara Therapeutics has a beta of -0.81, meaning that its share price is 181% less volatile than the broader market.

In the previous week, Bicara Therapeutics had 2 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 2 mentions for Bicara Therapeutics and 0 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 0.00 equaled Bicara Therapeutics'average media sentiment score.

Company	Overall Sentiment
Indaptus Therapeutics	Neutral
Bicara Therapeutics	Neutral

Summary

Bicara Therapeutics beats Indaptus Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Indaptus Therapeutics compare to Trulieve Cannabis?

Indaptus Therapeutics (NASDAQ:INDP) and Trulieve Cannabis (NYSE:TRLV) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations.

Trulieve Cannabis' return on equity of 0.00% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indaptus Therapeutics	N/A	-1,030.07%	-299.69%
Trulieve Cannabis	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Trulieve Cannabis	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Trulieve Cannabis has higher revenue and earnings than Indaptus Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$15.40	N/A
Trulieve Cannabis	$1.17B	1.60	N/A	N/A	N/A

In the previous week, Trulieve Cannabis had 1 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 1 mentions for Trulieve Cannabis and 0 mentions for Indaptus Therapeutics. Trulieve Cannabis' average media sentiment score of 0.61 beat Indaptus Therapeutics' score of 0.00 indicating that Trulieve Cannabis is being referred to more favorably in the news media.

Company	Overall Sentiment
Indaptus Therapeutics	Neutral
Trulieve Cannabis	Positive

7.1% of Indaptus Therapeutics shares are held by institutional investors. 23.6% of Indaptus Therapeutics shares are held by insiders. Comparatively, 3.8% of Trulieve Cannabis shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Trulieve Cannabis beats Indaptus Therapeutics on 6 of the 8 factors compared between the two stocks.

How does Indaptus Therapeutics compare to GH Research?

Indaptus Therapeutics (NASDAQ:INDP) and GH Research (NASDAQ:GHRS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

In the previous week, Indaptus Therapeutics' average media sentiment score of 0.00 equaled GH Research'saverage media sentiment score.

Company	Overall Sentiment
Indaptus Therapeutics	Neutral
GH Research	Neutral

GH Research is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$15.40	N/A
GH Research	N/A	N/A	-$48.26M	-$0.92	N/A

Indaptus Therapeutics has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market. Comparatively, GH Research has a beta of 1.28, suggesting that its share price is 28% more volatile than the broader market.

7.1% of Indaptus Therapeutics shares are held by institutional investors. Comparatively, 56.9% of GH Research shares are held by institutional investors. 23.6% of Indaptus Therapeutics shares are held by insiders. Comparatively, 41.6% of GH Research shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

GH Research's return on equity of -19.36% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indaptus Therapeutics	N/A	-1,030.07%	-299.69%
GH Research	N/A	-19.36%	-18.73%

GH Research has a consensus price target of $40.38, suggesting a potential upside of 49.48%. Given GH Research's stronger consensus rating and higher probable upside, analysts clearly believe GH Research is more favorable than Indaptus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
GH Research	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Summary

GH Research beats Indaptus Therapeutics on 9 of the 11 factors compared between the two stocks.

Get Indaptus Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INDP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INDP vs. The Competition

Export

Metric	Indaptus Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$343.12M	$3.10B	$7.17B	$12.48B
Dividend Yield	N/A	2.05%	2.66%	6.52%
P/E Ratio	-0.20	20.06	28.02	24.70
Price / Sales	N/A	360.33	540.72	98.05
Price / Cash	N/A	57.49	49.26	57.09
Price / Book	2.16	4.32	10.96	6.46
Net Income	-$20.85M	$64.45M	$3.57B	$337.01M
7 Day Performance	-10.41%	2.97%	2.12%	1.69%
1 Month Performance	-17.21%	6.83%	5.25%	3.81%
1 Year Performance	-70.35%	29.07%	33.29%	23.90%

Indaptus Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INDP Indaptus Therapeutics	0.2306 of 5 stars	$3.03 flat	N/A	-70.4%	$343.12M	N/A	N/A	6	Gap Down
RXRX Recursion Pharmaceuticals	3.2228 of 5 stars	$3.23 +2.2%	$8.10 +150.8%	-27.8%	$1.67B	$74.68M	N/A	400	Options Volume
SEPN Septerna	2.5199 of 5 stars	$36.05 -1.4%	$45.78 +27.0%	+200.9%	$1.65B	$45.95M	N/A	N/A	News Coverage Analyst Forecast Insider Trade
BCAX Bicara Therapeutics	0.8431 of 5 stars	$25.62 +2.5%	$30.27 +18.2%	+219.6%	$1.64B	N/A	N/A	32	News Coverage
TRLV Trulieve Cannabis	1.5321 of 5 stars	$8.53 0.0%	N/A	N/A	$1.64B	$1.17B	N/A	9,000	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INDP) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Indaptus Therapeutics (INDP) Competitors

INDP vs. RXRX, SEPN, BCAX, TRLV, and GHRS

How does Indaptus Therapeutics compare to Recursion Pharmaceuticals?

Summary

How does Indaptus Therapeutics compare to Septerna?

Summary

How does Indaptus Therapeutics compare to Bicara Therapeutics?

Summary

How does Indaptus Therapeutics compare to Trulieve Cannabis?

Summary

How does Indaptus Therapeutics compare to GH Research?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INDP vs. The Competition

Indaptus Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Indaptus Therapeutics (INDP) Competitors

INDP vs. RXRX, SEPN, BCAX, TRLV, and GHRS

How does Indaptus Therapeutics compare to Recursion Pharmaceuticals?

Which has more risk and volatility, RXRX or INDP?

Do institutionals & insiders believe in RXRX or INDP?

Is RXRX or INDP more profitable?

Do analysts recommend RXRX or INDP?

Which has higher earnings & valuation, RXRX or INDP?

Does the media prefer RXRX or INDP?

Summary

How does Indaptus Therapeutics compare to Septerna?

Do analysts rate SEPN or INDP?

Does the media prefer SEPN or INDP?

Do insiders & institutionals hold more shares of SEPN or INDP?

Which has more risk and volatility, SEPN or INDP?

Which has higher valuation and earnings, SEPN or INDP?

Is SEPN or INDP more profitable?

Summary

How does Indaptus Therapeutics compare to Bicara Therapeutics?

Do institutionals and insiders have more ownership in INDP or BCAX?

Do analysts recommend INDP or BCAX?

Which has stronger valuation and earnings, INDP or BCAX?

Is INDP or BCAX more profitable?

Which has more volatility & risk, INDP or BCAX?

Does the media favor INDP or BCAX?

Summary

How does Indaptus Therapeutics compare to Trulieve Cannabis?

Is INDP or TRLV more profitable?

Do analysts rate INDP or TRLV?

Which has better earnings and valuation, INDP or TRLV?

Does the media prefer INDP or TRLV?

Do institutionals & insiders have more ownership in INDP or TRLV?

Summary

How does Indaptus Therapeutics compare to GH Research?

Does the media favor INDP or GHRS?

Which has stronger earnings and valuation, INDP or GHRS?

Which has more volatility & risk, INDP or GHRS?

Do institutionals & insiders have more ownership in INDP or GHRS?

Is INDP or GHRS more profitable?

Do analysts rate INDP or GHRS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INDP vs. The Competition

Indaptus Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools